Nontuberculous Mycobacteria Infection Pipeline Therapies and Latest Breakthroughs 2020

Nontuberculous Mycobacteria Infection Pipeline Therapies and Latest Breakthroughs 2020

“Nontuberculous Mycobacteria Infection Pipeline”
The Nontuberculous Mycobacteria Infection Pipeline are RHB-204: RedHill Biopharma Thiolanox: Novoteris, Molgradex: Savara, Arikayce: Insmed Incorporated, Nitric Oxide: Beyond Air and others. Of the emerging therapies, the most anticipated therapy in the NTM infections market to get launched is, Arikayce, an aminoglycoside antibacterial, of Insmed Incorporated.

Nontuberculous Mycobacterial Infections Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial Infections market.


Nontuberculous Mycobacteria Infection Disease Overview

Nontuberculous Mycobacterial Infection is caused by nontuberculous mycobacteria, which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.

The severity and signs and symptoms of infections vary with person to person. Sometimes NTM infections causes skin diseases and inflammations. People with underlying disease such COPD, asthma, cystic fibrosis, AAD, and other lung disease are at risk of developing Nontuberculous mycobacterial lung disease, however, in some rare cases, people with no history of lung disease can also get affected.


Know more about report offerings:


Key Companies in Nontuberculous Mycobacterial Infection Market

  • Insmed Incorporated
  • RedHill Biopharma
  • Novoteris
  • Savara
  • Beyond Air


Nontuberculous Mycobacterial Infection Pipeline Therapies

  • RHB-204: RedHill Biopharma
  • Thiolanox: Novoteris
  • Molgradex: Savara
  • Arikayce: Insmed Incorporated
  • Nitric Oxide: Beyond Air


Read More:


Of the emerging therapies, the most anticipated therapy in the NTM infections market to get launched is, Arikayce, an aminoglycoside antibacterial, of Insmed Incorporated.

A detailed picture of the Nontuberculous Mycobacterial Infections pipeline landscape is provided, which includes the disease overview and Nontuberculous Mycobacterial Infections treatment guidelines. The assessment part of the report embraces in-depth Nontuberculous Mycobacterial Infections commercial assessment and clinical assessment of the Nontuberculous Mycobacterial Infections pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacterial Infections collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Request For Sample Pages:


Scope of the report

  • The Nontuberculous Mycobacterial Infections report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Nontuberculous Mycobacterial Infections across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Nontuberculous Mycobacterial Infections therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Nontuberculous Mycobacterial Infections research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Nontuberculous Mycobacterial Infections.



Table of Contents

1. Report Introduction

2. Nontuberculous Mycobacterial Infections 

3. Nontuberculous Mycobacterial Infections Current Treatment Patterns

4. Nontuberculous Mycobacterial Infections – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Nontuberculous Mycobacterial Infections Late Stage Products (Phase-III)

7. Nontuberculous Mycobacterial Infections Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nontuberculous Mycobacterial Infections Discontinued Products

13. Nontuberculous Mycobacterial Infections Product Profiles

14. Nontuberculous Mycobacterial Infections Key Companies

15. Nontuberculous Mycobacterial Infections Key Products

16. Dormant and Discontinued Products

17. Nontuberculous Mycobacterial Infections Unmet Needs

18. Nontuberculous Mycobacterial Infections Future Perspectives

19. Nontuberculous Mycobacterial Infections Analyst Review  

20. Appendix

21. Report Methodology



About DelveInsight


DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Browse through our vast repository


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States